Brighton Jones LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,000 shares of the medical research company's stock after acquiring an additional 1,532 shares during the period. Brighton Jones LLC's holdings in Amgen were worth $9,035,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the stock. Centricity Wealth Management LLC acquired a new position in Amgen in the fourth quarter worth $25,000. Pinney & Scofield Inc. acquired a new stake in shares of Amgen during the fourth quarter worth $26,000. Ritter Daniher Financial Advisory LLC DE lifted its position in shares of Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares during the last quarter. Synergy Investment Management LLC acquired a new position in shares of Amgen in the 4th quarter valued at about $34,000. Finally, Atala Financial Inc bought a new stake in shares of Amgen during the 4th quarter valued at about $34,000. 76.50% of the stock is currently owned by institutional investors.
Amgen Price Performance
Shares of NASDAQ AMGN traded down $0.42 during midday trading on Wednesday, reaching $289.63. The company's stock had a trading volume of 2,024,818 shares, compared to its average volume of 2,816,959. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a market cap of $155.74 billion, a price-to-earnings ratio of 26.43, a price-to-earnings-growth ratio of 2.67 and a beta of 0.51. The company has a 50 day moving average price of $281.62 and a 200 day moving average price of $285.78. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The firm's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.96 earnings per share. On average, equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.
Insider Buying and Selling
In other news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president now owns 8,162 shares in the company, valued at $2,364,368.16. This represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.69% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on AMGN shares. Wall Street Zen upgraded Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Johnson Rice set a $294.00 price target on Amgen in a report on Wednesday, March 5th. Cantor Fitzgerald began coverage on Amgen in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price objective for the company. Finally, Morgan Stanley restated an "equal weight" rating on shares of Amgen in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Amgen has an average rating of "Hold" and an average target price of $309.22.
Read Our Latest Research Report on AMGN
Amgen Company Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading

Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.